Better diag­no­sis of acute heart fail­ure using Pronota’s nov­el bio­mark­er

Ghent, Belgium, 18 april 2013 – Two inde­pen­dent val­i­da­tion stud­ies demon­strate that Pronota’s bio­mark­er CD146 sig­nif­i­cant­ly improves the diag­no­sis of acute heart fail­ure for patients with short­ness of breath. The bio­mark­er, mea­sured in blood, pro­vides clin­i­cians with unique addi­tion­al infor­ma­tion allow­ing bet­ter treat­ment of this chal­leng­ing group of patients.

Current diag­no­sis for acute heart fail­ure is lim­it­ed

Current clin­i­cal prac­tice for triag­ing patients with short­ness of breath includes the mea­sure­ment of spe­cif­ic pep­tides (B-type natri­uret­ic pep­tides: BNP or NT-proBNP). Despite the wide­spread use of these bio­mark­ers, there is still much room for improve­ment. “Natriuretic pep­tides have become stan­dard tools to sup­port mak­ing the cor­rect diag­no­sis in patients with short­ness of breath. However, clin­i­cians clear­ly rec­og­nize the lim­i­ta­tions of natri­uret­ic pep­tides. The poten­tial val­ue of anoth­er bio­mark­er to improve the diag­nos­tic accu­ra­cy of BNP or NT-proBNP is con­sid­er­able,” com­ment­ed Prof. J. Januzzi (Massachusetts General Hospital, Harvard Medical School).

Pronota’s nov­el heart fail­ure mark­er for accu­rate diag­no­sis

Pronota iden­ti­fied the bio­mark­er CD146 from an unbi­ased pro­teomics effort. Its per­for­mance has now been con­firmed in two inde­pen­dent stud­ies total­ing over 500 patients. Prof. A. Mebazaa (INSERM, Paris, France), prin­ci­pal inves­ti­ga­tor for the val­i­da­tion stud­ies, com­ment­ed: “It is excit­ing to see that nov­el bio­mark­ers with under­ly­ing bio­log­i­cal process­es com­plete­ly dif­fer­ent from cur­rent­ly used bio­mark­ers can still be dis­cov­ered and val­i­dat­ed. This not only pro­vides more insight into the under­ly­ing dis­ease mech­a­nism, it also gives the physi­cian tools to improve the man­age­ment and care of heart fail­ure patients. Pronota’s approach in this respect is unique and has proven to deliv­er on numer­ous occa­sions.”

Launch fore­cast: 2014

“Data from ear­ly ver­i­fi­ca­tion and mark­er char­ac­ter­i­za­tion stud­ies were already high­ly excit­ing, but the recent inde­pen­dent val­i­da­tion stud­ies exceed­ed our expec­ta­tions and would not have been pos­si­ble with­out the sup­port of our net­work of key opin­ion lead­ers in the field” com­ment­ed Katleen Verleysen, CEO of Pronota NV. “We antic­i­pate launch­ing this prod­uct in 2014, so that clin­i­cians may get access to the tools they need to improve the treat­ment and care of their patients.”

Leave a Reply

Your email address will not be published. Required fields are marked *